Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)
Phase 1
Completed
Conditions
Pertussis
Interventions
Biological: aP booster
Biological: TdaP booster
Biological: Licensed TdaP booster (Boostrix®)
Subscribe
First Posted Date
2015-03-09
Last Posted Date
2016-03-24
Lead Sponsor
Novartis
Target Recruit Count
315
Registration Number
NCT02382913
Locations
🇧🇪
Site 02, Center for Vaccinology (CEVAC), Ghent University Hospital, Ghent, Belgium
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy